SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):  January 24, 2019
MERIDIAN BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)

Ohio
0-14902
31-0888197
(State or other jurisdiction of incorporation)
(Commission File Number)
 
(IRS Employer Identification No. )

3471 River Hills Drive, Cincinnati, Ohio
45244
(Address of principal executive offices)
(Zip Code)
 
Registrant's telephone number, including area code (513) 271-3700
 
(Former name or former address, if changed since last report.)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 ☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 ☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 ☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17CFR §240.12b-2).
Emerging growth company
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act



Item 5.07   Submission of Matters to a Vote of Security Holders.

The following matters were submitted to a vote of shareholders at the Company's Annual Meeting of Shareholders held on January 24, 2019:
 
(a)   Votes regarding the election of eight directors:

 Name
 For
 Withheld
Broker Non-Votes
       
 James M. Anderson
     34,273,033
     1,076,936
     4,443,913
 Dwight E. Ellingwood
     35,028,730
        321,239
     4,443,913
 Jack Kenny
     34,752,181
        597,788
     4,443,913
 John C. McIlwraith
     35,015,556
        334,413
     4,443,913
 David C. Phillips
     34,201,968
     1,148,001
     4,443,913
 John M. Rice, Jr.
     35,061,738
        288,231
     4,443,913
 Catherine A. Sazdanoff
     34,602,998
        746,971
     4,443,913
 Felicia Williams
     35,231,463
        118,506
     4,443,913

(b)   Advisory votes regarding named executive officer compensation:

For 
 Against
 Abstain
 Broker Non-Votes
34,210,282
1,070,965
68,722
4,443,913
 

(c)   Votes regarding the ratification of the Audit Committee's appointment of Grant Thornton LLP as the Company's Independent Registered Public Accountants for fiscal 2019:

 For
 Against
 Abstain
38,350,159
1,386,134
57,589


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
MERIDIAN BIOSCIENCE, INC.
Date:  January 25, 2019
 
 
 
 
By: /s/ Eric S. Rasmussen
    Executive Vice President and Chief Financial Officer
    (Principal Financial Officer)